We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
-9%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$353M
AUM Growth
+$12.9M
Cap. Flow
+$60.9M
Cap. Flow %
17.29%
Top 10 Hldgs %
42.16%
Holding
101
New
22
Increased
19
Reduced
17
Closed
34

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$8.16M
2
RXST icon
RxSight
RXST
+$7.8M
3
ESTA icon
Establishment Labs
ESTA
+$7.58M
4
CAPR icon
Capricor Therapeutics
CAPR
+$7.52M
5
CMPS
Compass Pathways
CMPS
+$7.22M

Top Sells

Rank Stock Value
1
VERA icon
Vera Therapeutics
VERA
+$11.2M
2
PCVX icon
Vaxcyte
PCVX
+$8.23M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$6.49M
4
IRTC icon
iRhythm Holdings
IRTC
+$6.38M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$5.27M

Sector Composition

Rank Sector Weight
1 Healthcare 91%
2 Consumer Staples 0.08%
3 Consumer Discretionary 0%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
51
CALL
Larimar Therapeutics
LRMR
$431M
$1.53M 0.43%
396,000
+200,000
+102% +$1.32M
PRQR icon
52
ProQR Therapeutics
PRQR
$267M
$1.52M 0.43%
+575,000
New +$1.83M
VERU icon
53
Veru
VERU
$37.7M
$1.32M 0.37%
202,853
– –
UNCY icon
54
Unicycive Therapeutics
UNCY
$139M
$1.17M 0.33%
147,300
– –
NVNO
55
enVVeno Medical
NVNO
$7.13M
$936K 0.27%
8,857
+2,031
+30% +$227K
BCYC
56
Bicycle Therapeutics
BCYC
$294M
$565K 0.16%
40,352
-44,648
-53% -$957K
PMN icon
57
ProMIS Neurosciences
PMN
$126M
$551K 0.16%
23,256
– –
FULC icon
58
Fulcrum Therapeutics
FULC
$296M
$526K 0.15%
+111,812
New +$412K
KPTI icon
59
Karyopharm Therapeutics
KPTI
$46.7M
$500K 0.14%
49,333
– –
CTMX icon
60
CytomX Therapeutics
CTMX
$753M
$482K 0.14%
467,491
-447,509
-49% -$481K
XENE icon
61
CALL
Xenon Pharmaceuticals
XENE
$6.14B
$368K 0.1%
9,400
– –
CATX icon
62
Perspective Therapeutics
CATX
$342M
$294K 0.08%
92,224
-197,776
-68% -$1.61M
SRXH
63
SRX Global
SRXH
$29.9M
$278K 0.08%
2,665
-330
-11% -$28.9K
ANAB icon
64
AnaptysBio
ANAB
$1.67B
$243K 0.07%
+18,326
New +$444K
QNRX
65
Quoin Pharmaceuticals
QNRX
$9.56M
$184K 0.05%
+8,064
New +$185K
CLRB icon
66
Cellectar Biosciences
CLRB
$20.2M
$64.3K 0.02%
7,167
– –
APLT
67
PUT
DELISTED
Applied Therapeutics
APLT
$48K 0.01%
56,100
– –
ANVS icon
68
PUT
Annovis Bio
ANVS
$78.7M
– –
-236,400
Closed -$1.91M
ATRC icon
69
AtriCure
ATRC
$2.09B
– –
-54,000
Closed -$1.51M
AXSM icon
70
Axsome Therapeutics
AXSM
$10.9B
– –
-58,000
Closed -$5.21M
BTMWW
71
DELISTED
Bitcoin Depot Inc Warrant
BTMWW
– –
-50,000
Closed -$2.5K
CDTTW
72
CDT Equity Inc Warrant
CDTTW
$1.87M
– –
-100,000
Closed -$1.59K
BNCWW
73
CEA Industries Inc Warrant
BNCWW
– –
-250,000
Closed -$6.28K
CINGW icon
74
Cingulate Inc Warrants
CINGW
$28.9K
– –
-270,000
Closed -$18.7K
HELP
75
Cybin Inc
HELP
$713M
– –
-317,000
Closed -$2.82M
1 2
3
4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CF
Crosspoint Financial Tustin, California $39.8M AUM 14.13% 1-Year Est. Return

Altium Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Altium Capital Management held 101 positions worth $353M, up 3.8% from $340M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Altium Capital Management deployed $60.9M of net new capital in Q4 2024, opening 22 new positions and adding to 19 existing holdings. Its largest new stake was Compass Pathways: 1,424,400 shares worth $5.38M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Vera Therapeutics, an estimated $11.2M trimmed.

  • Altium Capital Management's largest Q4 2024 buy was Compass Pathways: 1,424,400 shares worth $5.38M.
  • Altium Capital Management added most to Biohaven in Q4 2024, an estimated $8.16M increase.
  • Altium Capital Management's biggest Q4 2024 reduction was Vera Therapeutics, cutting an estimated $11.2M.
  • Altium Capital Management fully exited Vaxcyte in Q4 2024, selling an estimated $8.23M.
  • Altium Capital Management's ten largest holdings make up 42% of its $353M portfolio in Q4 2024.
  • Altium Capital Management opened 22 new positions and closed 34 in Q4 2024.
  • Altium Capital Management's portfolio value rose 3.8% quarter-over-quarter to $353M.

Based on Altium Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.